The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five …
R Nicholas, J Rodgers, J Witts… - Therapeutic …, 2023 - journals.sagepub.com
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple
sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT …
sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT …
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five …
R Nicholas, J Rodgers, J Witts, A Lerede… - Therapeutic …, 2023 - europepmc.org
Methods We analysed registry data from six cohorts in five countries (Czech Republic,
Denmark, Germany, Sweden and United Kingdom) on patients with an initial diagnosis of …
Denmark, Germany, Sweden and United Kingdom) on patients with an initial diagnosis of …
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five …
R Nicholas, J Rodgers, J Witts, A Lerede… - Therapeutic advances …, 2023 - diva-portal.org
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple
sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT …
sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT …
[PDF][PDF] The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective …
R Nicholas, J Rodgers, J Witts, A Lerede, T Friede… - 2023 - cronfa.swan.ac.uk
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple
sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT …
sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT …
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five …
R Nicholas, J Rodgers, J Witts, A Lerede… - 2023 - publications.goettingen-research …
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple
sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT …
sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT …
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five …
R Nicholas, J Rodgers, J Witts, A Lerede… - Therapeutic …, 2023 - research.regionh.dk
INTRODUCTION: Prescribing guidance for disease-modifying treatment (DMT) in multiple
sclerosis (MS) is centred on a clinical diagnosis of relapsing-remitting MS (RRMS). DMT …
sclerosis (MS) is centred on a clinical diagnosis of relapsing-remitting MS (RRMS). DMT …
[HTML][HTML] The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world …
R Nicholas, J Rodgers, J Witts, A Lerede… - Therapeutic …, 2023 - ncbi.nlm.nih.gov
Methods: We analysed registry data from six cohorts in five countries (Czech Republic,
Denmark, Germany, Sweden and United Kingdom) on patients with an initial diagnosis of …
Denmark, Germany, Sweden and United Kingdom) on patients with an initial diagnosis of …
[PDF][PDF] The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective …
R Nicholas, J Rodgers, J Witts, A Lerede, T Friede… - 2023 - pdfs.semanticscholar.org
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple
sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT …
sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT …
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five …
R Nicholas, J Rodgers, J Witts… - Therapeutic …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction Prescribing guidance for disease-modifying treatment (DMT) in multiple
sclerosis (MS) is centred on a clinical diagnosis of relapsing-remitting MS (RRMS). DMT …
sclerosis (MS) is centred on a clinical diagnosis of relapsing-remitting MS (RRMS). DMT …
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five …
R Nicholas, J Rodgers, J Witts, A Lerede, T Friede… - 2023 - europepmc.org
Methods: We analysed registry data from six cohorts in five countries (Czech Republic,
Denmark, Germany, Sweden and United Kingdom) on patients with an initial diagnosis of …
Denmark, Germany, Sweden and United Kingdom) on patients with an initial diagnosis of …